Drug Type Small molecule drug |
Synonyms Denfivontinib, G-749 Hydrochloride, G-801 + [1] |
Target |
Mechanism FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H26BrClN6O2 |
InChIKeyUDYYCTJUUMIMHX-UHFFFAOYSA-N |
CAS Registry1457983-33-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | KR | 25 Jan 2022 | |
Refractory acute myeloid leukemia | Phase 1 | US | 23 Feb 2018 | |
Relapsing acute myeloid leukemia | Phase 1 | US | 23 Feb 2018 |